Moderna Begins Late-Stage Bird Flu Vaccine Trial

Key Development in Pandemic Preparedness

Moderna has launched the first-ever late-stage clinical trial for an mRNA-based pandemic bird flu vaccine, known as mRNA-1018. The study will enroll approximately 4,000 healthy adults across the United States and the United Kingdom, marking a significant milestone for vaccine technology.

Trial Overview and Funding

The trial is supported by a $54 million investment from the Coalition for Epidemic Preparedness Innovations CEPI. This initiative underscores the potential of mRNA technology, which was used for COVID-19 vaccines, to enable rapid development against emerging viral threats. CEO Stephane Bancel stated that bird flu remains a persistent pandemic threat, and this study is a crucial step in improving preparedness.

Market and Regulatory Outlook

A successful trial could strengthen Moderna's vaccine portfolio and its role in global public health security. The company noted that any future regulatory submission for mRNA-1018 would also be supported by positive data from its seasonal flu vaccine candidate, mRNA-1010. Per its agreement with CEPI, Moderna has committed 20% of its manufacturing capacity to low and middle-income nations at affordable prices if a flu pandemic is declared.

Summary

This late-stage trial represents a critical advancement in leveraging mRNA technology for future pandemic responses. Investors and public health officials will closely watch the trial's progress as it could influence future vaccine development strategies and Moderna's market position.

FAQ

Q: What is the name of Moderna's bird flu vaccine candidate?
A: The vaccine is designated as mRNA-1018.

Q: How many participants are in the trial?
A: The trial will test the vaccine on about 4,000 healthy adults aged 18 and older.

Source: Investing.com